1. United States of America Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Kenvue Inc.

Kenvue Inc.

KVUE
Kenvue Inc.US flagNew York Stock Exchange
17.87
USD
+0.07
- -
34.30BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.58
7.66
7.97
7.91
8.37
8.07
7.89
8.03
Basic EPS, GAAP
0.76
-0.47
1.1
1.09
0.9
0.54
0.77
0.86
Free Cash Flow per Basic Share
1.43
1.68
0.02
1.14
1.46
0.7
0.9
1
Dividend per Share
- -
- -
- -
- -
7.88
0.81
0.82
0.83
Book Value per Share
- -
9.72
10.8
10.57
5.85
5.05
5.62
5.5
Tangible Book Value per Share
- -
-1.9
-0.06
0.49
-4.01
-4
-3.88
-3.71
Basic Weighted Avg Shares
1,889
1,889
1,889
1,889
1,846
1,915
1,917
1,918
Sales/Revenue/Turnover
14,324
14,467
15,054
14,950
15,444
15,455
15,124
15,408
Operating Margin (%)
16.75
20.65
20.15
17.98
16.14
17.01
17.95
19.09
Depreciation Expense
709
746
731
644
627
622
557
567
Net Income, GAAP
1,435
-879
2,078
2,064
1,664
1,030
1,470
1,658
Effective Tax Rate (%)
32.31
- -
28.96
21.73
24.02
27.21
26.46
25.42
Profit Margin (%)
10.02
-6.08
13.8
13.81
10.77
6.66
9.72
10.76
Working Capital
- -
-2,899
885
1,951
657
-214
-248
32
LT Debt
- -
- -
82
81
7,784
7,132
7,178
7,166
Total Equity
- -
18,356
20,399
19,970
11,211
9,668
10,765
10,553
Return on Invested Capital (%)
- -
- -
10.9
10.21
9.41
9.97
10.49
11.3
Return on Capital (%)
- -
- -
10.69
10.16
9.75
7.07
9.44
10.22
Return on Common Equity (%)
- -
-9.58
10.72
10.23
10.67
9.87
14.39
15.58

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,496
1,631
1,447
LT Borrowings
6,938
7,072
7,074
LT Finance Leases
240
99
92
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,916
1,920
1,920
Market Capitalization
33,053
33,100
36,696

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,697
5,795
5,899
Cash, Cash Equivalents & STI
1,062
1,075
1,110
Accounts Receivable, Net
2,382
2,501
2,476
Inventories
1,666
1,674
1,722
Total Current Liabilities
5,945
5,896
5,867
Payables & Accruals
4,106
4,046
4,106
ST Debt
1,496
1,631
1,447
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.45%
11.35%
Free Cash Flow
- -
1,063.61%
28.99%
Net Income, GAAP
- -
-70.37%
42.72%
Sales/Revenue/Turnover
- -
0.92%
-2.14%
Total Cash Common Dividend
- -
- -
1.87%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,894
4,000
3,899
3,662
15,455
2025
3,741
3,839
3,764
3,780
15,124
2026
3,909
3,955
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.03
0.2
0.15
0.54
2025
0.17
0.22
0.21
0.17
0.77
2026
0.25
0.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.2
0.21
0.21
0.81
2025
0.2
0.2
0.21
0.21
0.82
2026
0.21
0.21
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kirk L. Perry
Full Time Employees
21,890
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
1 Kenvue Way Summit NJ United States of America 07901
IPO Date
May 4, 2023
CIK
0001944048
Website
kenvue.com
Similar Companies
Asian Phytoceuticals Public Co. Ltd. (APCO.BK)
Prenetics Global Limited (PRENW)
Axil Brands, Inc. (AXIL)
Instinct Bio Technical Co. Holdings Inc. (BIOT)
The Honest Company, Inc. (HNST)
Spectrum Brands Holdings, Inc. (SPB)
Business
Kenvue Inc. Kenvue Inc. (KVUE) operates as the world's largest pure-play consumer health company by revenue, focusing on science-backed everyday care products that serve over 1.2 billion people daily across more than 100 countries including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company manages three core segments: Self Care, offering cough, cold and allergy remedies, pain care, digestive health, smoking cessation, eye care, and related products under brands such as Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSL, Rhinocort, Calpol, and Zyrtec; Skin Health and Beauty, providing face and body care, hair, sun, and other solutions via Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX; and Essential Health, encompassing oral care, baby care, women’s health, wound care, and other items through Listerine, Johnson’s, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash. Incorporated in 2022 as a spin-off from Johnson & Johnson Johnson & Johnson and headquartered in Summit, New Jersey, Kenvue draws on a heritage exceeding 135 years in consumer health innovation. In November 2025, Kimberly-Clark Corporation Kimberly-Clark Corporation agreed to acquire Kenvue in a $48.7 billion cash-and-stock transaction valued at approximately $21.01 per share, representing a 33% premium to recent trading levels and creating a combined consumer health and wellness entity with projected $2.1 billion in annual synergies by 2028, subject to regulatory approvals expected in the second half of 2026. Earlier in 2025, Kenvue opened its new 290,000-square-foot global headquarters in Summit, New Jersey, featuring a 100,000-square-foot Science and Innovation Lab to consolidate operations, accelerate R&D, and enhance proximity to talent and consumers; launched the Tylenol Proactive Support supplement line for joint care; initiated the Total Quit campaign advocating tobacco and nicotine regulation; and appointed Kirk Perry as permanent CEO following a strategic review amid leadership transitions.

Company News

Company News APIChatGPT

  • etftrends.com

    Burning a Hole in My Pocket

  • reuters.com

    Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal

  • 247wallst.com

    5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)

  • 247wallst.com

    The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20

  • defenseworld.net

    Kenvue Inc. $KVUE Shares Sold by Corient Private Wealth LP

  • fool.com

    Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

  • fool.com

    Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

  • reuters.com

    Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say

  • 247wallst.com

    Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal

  • etftrends.com

    My Favorite Consumer Staples Play Right Now

  • businesswire.com

    Kenvue Declares Quarterly Cash Dividend

  • zacks.com

    Kenvue's Brand Strength and Innovation Strategy Support Growth

  • zacks.com

    Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

  • zacks.com

    Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

  • reuters.com

    Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment

  • reuters.com

    Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

  • defenseworld.net

    43,671 Shares in Kenvue Inc. $KVUE Purchased by Callan Family Office LLC

  • defenseworld.net

    32,710 Shares in Kenvue Inc. $KVUE Purchased by AssuredPartners Investment Advisors LLC

  • defenseworld.net

    B & T Capital Management DBA Alpha Capital Management Makes New Investment in Kenvue Inc. $KVUE

  • prnewswire.com

    Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel